Abstract：
Psoriasis is a chronic immune-mediated disease of the skin. The incidence of psoriasis among people living with HIV (PLHIV) is higher than that in the general population. The mechanism is complex, the manifestations are varied, and the treatment is difficult. Biotherapy has greatly alleviated psoriasis, but clinical trials often exclude PLHIV, and evidence is limited to case reports. Here, we report a man living with psoriatic arthritis who had poor response to traditional treatments. After receiving the anti-interleukin (IL)-17 monoclonal antibody (ixekizumab), the arthritis symptoms were significantly relieved, while CD4+ T cell count increased and the viral load of HIV-1 remained undetectable in combination with antiretroviral therapy (ART). In conclusion, anti-IL-17 monoclonal antibody is a promising and safe treatment for psoriatic arthritis in HIV-positive patients.
摘要：
银屑病是一种慢性免疫介导的皮肤病。HIV感染者(PLHIV)中银屑病的发病率高于普通人群。机制很复杂,表现形式是多种多样的，治疗很困难。生物疗法大大缓解了牛皮癣，但是临床试验通常排除PLHIV，证据仅限于病例报告。这里,我们报告了一名患有银屑病关节炎的男子，他对传统治疗反应不佳。在接受抗白细胞介素（IL）-17单克隆抗体（ixekizumab）后，关节炎症状明显缓解,而与抗逆转录病毒治疗（ART）联合使用时，CD4+T细胞计数增加，HIV-1的病毒载量仍未检测到。总之,抗IL-17单克隆抗体是治疗HIV阳性患者银屑病关节炎的一种有前途且安全的治疗方法.
